Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

Journal of Virology
Edward N van den BrinkJaap Goudsmit


Human monoclonal antibodies (MAbs) were selected from semisynthetic antibody phage display libraries by using whole irradiated severe acute respiratory syndrome (SARS) coronavirus (CoV) virions as target. We identified eight human MAbs binding to virus and infected cells, six of which could be mapped to two SARS-CoV structural proteins: the nucleocapsid (N) and spike (S) proteins. Two MAbs reacted with N protein. One of the N protein MAbs recognized a linear epitope conserved between all published human and animal SARS-CoV isolates, and the other bound to a nonlinear N epitope. These two N MAbs did not compete for binding to SARS-CoV. Four MAbs reacted with the S glycoprotein, and three of these MAbs neutralized SARS-CoV in vitro. All three neutralizing anti-S MAbs bound a recombinant S1 fragment comprising residues 318 to 510, a region previously identified as the SARS-CoV S receptor binding domain; the nonneutralizing MAb did not. Two strongly neutralizing anti-S1 MAbs blocked the binding of a recombinant S fragment (residues 1 to 565) to SARS-CoV-susceptible Vero cells completely, whereas a poorly neutralizing S1 MAb blocked binding only partially. The MAb ability to block S1-receptor binding and the level of neutralization ...Continue Reading


Dec 5, 1991·Journal of Molecular Biology·J D MarksG Winter
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·H M GeysenR H Meloen
Jul 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·H M GeysenS J Barteling
Oct 12, 2000·Clinical Microbiology Reviews·M A Keller, E R Stiehm
Mar 10, 2001·Journal of Virology·M J HavengaP H Quax
Jul 30, 2002·The Lancet Infectious Diseases·Charles E RupprechtThiravat Hemachudha
Apr 12, 2003·The New England Journal of Medicine·Christian DrostenHans Wilhelm Doerr
Apr 12, 2003·The New England Journal of Medicine·Thomas G KsiazekUNKNOWN SARS Working Group
Apr 25, 2003·Lancet·J S M PeirisUNKNOWN SARS study group
May 16, 2003·Nature·Ron A M FouchierAlbert D M E Osterhaus
Jun 5, 2003·Lancet·John M NichollsJ S Malik Peiris
Jun 5, 2003·The Journal of Clinical Investigation·Kathryn V Holmes
Aug 2, 2003·The New England Journal of Medicine·Gang LiAnlong Xu
Oct 31, 2003·Nature·Byron E E MartinaAlbert D M E Osterhaus
Dec 4, 2003·Biochemical and Biophysical Research Communications·Xiaodong XiaoDimiter S Dimitrov
Dec 13, 2003·The Journal of Biological Chemistry·Swee Kee WongMichael Farzan
Jan 31, 2004·Science·UNKNOWN Chinese SARS Molecular Epidemiology Consortium
Feb 26, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jianhua SuiWayne A Marasco
Mar 20, 2004·Emerging Infectious Diseases·Bo Jian ZhengShui Shan Lee
Jun 29, 2004·Lancet·Jan ter MeulenAlbert D M E Osterhaus

❮ Previous
Next ❯


Dec 11, 2007·Nature Biotechnology·Wayne A Marasco, Jianhua Sui
Feb 10, 2009·Nature Reviews. Microbiology·Lanying DuShibo Jiang
Jun 15, 2007·Antioxidants & Redox Signaling·Emmanuel FenouilletIan M Jones
Oct 17, 2006·Clinical Microbiology Reviews·Laura Gillim-Ross, Kanta Subbarao
Mar 1, 2013·Immunotherapy·Heinz Kohler
Jul 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·Zhongyu ZhuDimiter S Dimitrov
Feb 17, 2009·Expert Opinion on Biological Therapy·Ponraj PrabakaranDimiter S Dimitrov
Mar 6, 2007·Journal of Immunological Methods·Nileena VelappanAndrew R M Bradbury
Jun 29, 2006·Annals of the New York Academy of Sciences·Morten Draeby SørensenPeter Kristensen
Jun 9, 2005·Biochemical and Biophysical Research Communications·Jinzhu DuanGang Jin
Feb 15, 2007·Travel Medicine and Infectious Disease·Johannes Antonie BogaardsJaap Goudsmit
Aug 3, 2013·Expert Opinion on Therapeutic Patents·Vathan KumarPo-Huang Liang
Jan 31, 2006·Expert Review of Anti-infective Therapy·Zhongyu ZhuDimiter S Dimitrov
May 17, 2012·Viruses·Taylor Heald-Sargent, Tom Gallagher
Jun 23, 2005·European Journal of Immunology·R Arjen KramerJohn de Kruif
May 20, 2009·Expert Opinion on Therapeutic Patents·Tommy R Tong
Aug 9, 2020·Expert Opinion on Biological Therapy·Mehrnoosh Pashaei, Nima Rezaei
Sep 10, 2020·PloS One·Lluc Farrera-SolerNicolas Winssinger
Jun 24, 2020·Frontiers in Immunology·Gabriel SiracusanoLucia Lopalco
Aug 18, 2020·International Journal of General Medicine·Solmaz Ohadian Moghadam
Jan 14, 2011·The Journal of General Virology·Juan RegueraJosé M Casasnovas
May 12, 2020·Frontiers in Microbiology·Longping V TseRalph S Baric
Jan 17, 2019·Viruses·Zhiqi SongChuan Qin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.